Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Algernon Pharmaceuticals Inc (OP: AGNPF )

0.0520 UNCHANGED
Streaming Delayed Price Updated: 10:40 AM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Algernon Pharmaceuticals Inc

Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Via Benzinga
DMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial Design
Via Benzinga
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
Via Benzinga
DMT As A Treatment For Stroke? This Company Is Closer To Launching Its Phase 2 Study
Algernon NeuroScience (AGN Neuro), a subsidiary of Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) (CSE:AGN) (FRANKFURT:AGW0), has completed a feasibility study and has finalized its clinical trial design... 
Via Benzinga
Algernon Posts Mixed Bag Results From Mid Stage Chronic Cough Study
Via Benzinga
DMT's Clinical Path For Treating TBI And Stroke: Phase 1 Dosing Finished As Phase 2 Gears Up
Algernon Pharmaceuticals’ (OTCQB: AGNPF) wholly-owned Algernon NeuroScience (AGN Neuro) successfully completed dosing the third and final cohort of its Phase 1 clinical study assessing an intravenous... 
Via Benzinga
How To Finance A Psychedelics Business? Learn From These Four Companies
Clearmind Medicine Announces Pricing of $3.5 Million Public Offering 
Via Benzinga
Intravenous DMT Therapy Seeks Ideal Dosage For Stroke And TBI Treatment
Canadian biopharma company Algernon Pharmaceuticals Inc. 
Via Benzinga
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been... 
Via Benzinga
Algernon Pharmaceuticals AP-188 DMT Compound Shows Promise For The Treatment Of TBI
In this new podcast, TDR Founder Shadd Dales interviewed Algernon Pharmaceuticals (OTC: AGNPF) CEO, Christopher Moreau. 
Via Benzinga
Algernon Pharmaceuticals Goes 4:1 In Forward Share Split After Announcing New TBI Program
Canadian clinical-stage psychedelics developer Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) will start trading its Class A common shares following a 4-to-1 stock split towards increasing liquidity.  
Via Benzinga
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and... 
Via Benzinga
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and... 
Via Benzinga
Developing Psychedelic Treatments For Traumatic Brain Injury: Algernon Launches New Program
Biopharma company Algernon Pharmaceuticals (OTCQB: AGNPF) has launched a new clinical research program via a subsidiary. 
Via Benzinga
Algernon Touts Positive Study Findings, Confirms Next Trial Phase With Escalated Dose
Algernon Pharmaceuticals (OTCQB: AGNPF)’s subsidiary Algernon NeuroScience has completed the first cohort in its Phase 1 clinical study of 
Via Benzinga
A Psychedelic Program For Treatment Of Stroke: New Clinical Trial Begins Dosing
Canadian clinical-stage psychedelics company Algernon Pharmaceuticals (OTCQB: AGNPF)’s newly created subsidiary Algernon NeuroScience (AGN Neuro) has dosed 
Via Benzinga
Psychedelic Subsidiaries News: Blackhawk Spins Out Three Companies, Algernon Creates A New One
The psychedelics space is up and running. Together with the start of the new year, two companies have shared their latest financial decisions toward advancing their medical business programs. 
Via Benzinga
EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans
Part one of a three-part series. The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. 
Via Benzinga
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy 
Via Benzinga
Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon
Canadian clinical-stage psychedelics company Algernon Pharmaceuticals Inc. 
Via Benzinga
Tackling Depression With Psychedelics: New Phase 2 Clinical Study Begins At Yale University
Canadian-based psychedelics biopharma company Algernon Pharmaceuticals Inc. 
Via Benzinga
A Foundational Study On Stroke Is Ready. Here Is Why It's Important
Biopharma company Algernon Pharmaceuticals Inc's (OTC: AGNPF) recently announced plan for a Phase 1 clinical study on DMT for huma 
Via Benzinga
Canadian Psychedelics Company To Begin First Global DMT Clinical Trial For Stroke Treatment
Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has set up a clinical research program for the treatment of strokes, focused on its proprietary DMT analogue, AP-188. The company is also planning to begin... 
Via Benzinga
Algernon Pharmaceuticals Closes Private Placement Round, Announces New Shareholder Distribution
Biotech clinical-stage company Algernon Pharmaceuticals Inc. 
Via Benzinga
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
The Week In Psychedelics 
Via Benzinga
Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics
Last Week In Psychedelics: 
Via Benzinga
How To Invest In "Magic Mushrooms" (Psychedelics)
A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest. 
Via Talk Markets
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
Via Benzinga
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps... 
Via Benzinga
Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform
Atai Life Sciences (NASDAQ: ATAI) made its highly-anticipated Nasdaq... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.